Distinguishing PV and MF From Other Conditions
Expert Viewpoints: Managing Select Cases in PV
- General approach to treatment
- Aggressive vs indolent disease phenotypes
- Higher-risk PV
- Uncontrolled/treatment-refractory PV
Expert Viewpoints: Managing Select Cases in MF
- General approach to treatment
- Symptomatic, low-risk/intermediate1–risk MF
- Intermediate 2–risk/high-risk MF
Emerging Investigational Agents and Approaches for Managing PV and MF
Date / Time
Brady L. Stein, MD, MHS
Assistant Professor of Medicine
Northwestern University Feinberg School of Medicine
Srdan Verstovsek, MD, PhD
Division of Cancer Medicine
Department of Leukemia
The University of Texas M. D. Anderson Cancer Center
The goal of this activity is to improve participants’ competence in and performance at treating patients with polycythemia vera and myelofibrosis.
This program is intended for physicians, registered nurses, pharmacists, and other healthcare providers who care for patients with myelofibrosis or polycythemia vera.
- Utilize clinical tools and evidence to help to distinguish the PV and MF from reactive conditions
- Recognize the clinical impact of molecular mutations on diagnosis, prognosis, and treatment choices for patients with PV and MF
- Analyze current and emerging clinical trial data of JAK 1/2 inhibitors in PV and MF
- Tailor therapy for patients with PV and MF, using evidence-based guidance on best practices, safety considerations, and new data across the range of treatment settings
- Identify ongoing trials for the treatment of PV and MF to aid referral of patients for study participation
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
This educational activity for 1.0 contact hour is provided by Postgraduate Institute for Medicine.
Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 1.0 contact hour.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you within 3 weeks.
Pharmacist Continuing Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - 0809-9999-17-851-L01-P
Type of Activity
Upon completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.